Aminoglycoside pharmacokinetic parameters were studied prospectively in 27 patients with an underlying hematologic malignancy and fever associated with neutropenia and in 18 control patients. Pharmacokinetic parameters and dosages were determined by linear regression analysis of a one-compartment model by the method of Sawchuk et al. (R. J. Sawchuk, D. E. Zaske, R. J. Cippolle, W. A. Wargin, and R. G. Strate, Clin. Pharmacol. Ther. 21:362-369, 1976 Aminoglycosides remain one of the most important groups of antibiotics in the treatment of gram-negative infections (25). To maximize efficacy and minimize toxicity with these agents, determination of the drug concentration in serum is necessary (1, 30) . Achieving a peak concentration in serum (Cmax) for gentamicin or tobramycin of 6 to 8 ,ug/ml and for amikacin of 20 to 28 ,ug/ml is associated with improved survival in patients with gram-negative bacteremias and pneumonias (1, 17, (25) (26) (27) (32) and observed that doses higher than those recommended by the manufacturer were needed in order to achieve therapeutic aminoglycoside concentrations in serum (unpublished data). Hence, we set out a prospective controlled study to determine the aminoglycoside pharmacokinetic parameters in patients with an underlying hematologic malignancy. In this report we describe the details of our results and propose new aminoglycoside dosage guidelines for adult patients with an underlying hematologic malignancy.
Aminoglycoside pharmacokinetic parameters were studied prospectively in 27 patients with an underlying hematologic malignancy and fever associated with neutropenia and in 18 control patients. Pharmacokinetic parameters and dosages were determined by linear regression analysis of a one-compartment model by the method of Sawchuk et al. (R. J. Sawchuk, D. E. Zaske, R. J. Cippolle, W. A. Wargin, and R. G. Strate, Clin. Pharmacol. Ther. 21:362-369, 1976 ). Significant differences between the study and control groups were found for aminoglycoside volume of distribution (0.40 0.1 versus 0.27 0.05 liter/kg [mean ± standard deviation], respectively; P < 0.0001), clearance (116.6 48.9 versus 68.6 26.7 ml/min, respectively; P < 0.0001), half-life (2.27 + 0.66 versus 3.5 1.8 h, respectively; P < 0.0001), and elimination rate constant (0.33 0.11 versus 0.24 0.09 h-1, respectively; P < 0.001). The percentage of bone marrow blast cells (at the time of diagnosis) in patients with acute leukemia significantly correlated with increased aminoglycoside clearance (R12 = 36.98%; P = 0.0001). Patients with stage IV lymphomas (Hodgkins disease and non-Hodgkins lymphoma) had a significantly increased clearance compared with patients with lower stages of lymphomas (105.1 _ 18.5 versus 84.1 14.9 ml/min; P = 0.014). Fever, leukocyte count, or chemotherapy, among other clinical and laboratory parameters that were studied, had no significant correlation or effect on aminoglycoside disposition. The average dose of amikacin required to maintain peak concentrations in serum above 20 ,ug/ml in patients with a hematologic malignancy was 27.5 8.43 mg/kg per day. Pharmacokinetic parameters and dosages for the control patients were comparable to general literature standards. We conclude that the dosages recommended by the manufacturers or those derived from nomograms underestimate the aminoglycoside volume of distribution and clearance in patients with a hematologic malignancy and result in suboptimal peak aminoglycoside concentrations in serum. We recommend that in febrile neutropenic patients with an underlying hematologic malignancy, amikacin be initiated at 7.5 to 10 mg/kg per dose every 8 h (2 to 2.5 mg/kg per dose every 8 h for gentamicin) and adjusted within 24 h based on individual pharmacokinetic analysis.
Aminoglycosides remain one of the most important groups of antibiotics in the treatment of gram-negative infections (25) . To maximize efficacy and minimize toxicity with these agents, determination of the drug concentration in serum is necessary (1, 30) . Achieving a peak concentration in serum (Cmax) for gentamicin or tobramycin of 6 to 8 ,ug/ml and for amikacin of 20 to 28 ,ug/ml is associated with improved survival in patients with gram-negative bacteremias and pneumonias (1, 17, (25) (26) (27) . The two major factors that determine the value of the Cma are the dose and the apparent volume of distribution (Vss) of the drug. The Cm. is directly related to the dose and is inversely related to the V., Aminoglycoside dosage nomograms as well as manufacturer-recommended doses assume a constant Vss of approximately 0.25 liter/kg of body weight (3, 6, 16) . It has been observed that in certain patient groups (i.e., those with burns [41] , with cystic fibrosis [18] , in intensive care units [14] , in the postoperative period [29] ) the Vs, is increased. Dosage schedules based on nomograms and manufacturer-recommended guidelines lead to underestimation of the Vss and, hence, subtherapeutic aminoglycoside Cmax values in these patient populations (14, 18, 22, 29, 41) .
Optimal aminoglycoside dosage is particularly important in febrile neutropenic patients. It has been shown that neutropenic patients with gram-negative bacterial infections require higher peak bactericidal concentrations in serum to improve their outcome when compared with those required in nonneutropenic patients (34) .
Despite (32) and observed that doses higher than those recommended by the manufacturer were needed in order to achieve therapeutic aminoglycoside concentrations in serum (unpublished data). Hence, we set out a prospective controlled study to determine the aminoglycoside pharmacokinetic parameters in patients with an underlying hematologic malignancy. In this report we describe the details of our results and propose new aminoglycoside dosage guidelines for adult patients with an underlying hematologic malignancy. Patients in the study group were newly diagnosed, in documented relapse, or at various stages of their treatment (induction, reinduction, consolidation, maintenance). Eighteen randomly selected age-and sex-matched adults receiving aminoglycosides for gram-negative bacterial infections (urinary tract infections, diabetic foot ulcers, osteomyelitis, bacteremia, and hospital-acquired pneumonias) admitted to the general medical wards, who did not meet the exclusion criteria, served as controls. Control patients had no underlying malignancy and were otherwise healthy adults, aside from their primary medical problem. All patients were of Arab origin, and their characteristics are described in Table  1 . Neutropenia was defined as an absolute neutrophil count of <1,000/mm3. Fever was defined as an oral temperature of >38.5°C on one occasion or >38°C on two occasions in a 24-h period at least 4 h apart that was unrelated to the use of drugs or infusion of blood products.
Patients with ascites, pleural effusions, major surgery, creatinine levels in serum of > 196 ,umol/liter, or septic shock prior to the initiation of aminoglycoside therapy were excluded from the study and control groups, as these conditions may alter aminoglycoside disposition (24, 39) .
Antibiotic treatment. Empiric therapy consisted of intravenous ceftazidime (2 g every 8 h) in combination with intravenous amikacin (7.5 mg/kg every 12 h) or gentamicin (1.3 mg/kg every 8 h) (actual body weight was used in all but one patient, who was obese; lean body weight was used in the obese patient). Vancomycin, metronidazole, amphotericin B, or acyclovir was added as indicated.
Pharmacokinetic analysis. Serum samples were collected after at least five estimated half-lives of the aminoglycoside had elapsed, usually 24 h, to ensure that steady-state concentrations in serum were achieved. A predose sample (Cmin) was taken immediately prior to administration of the next scheduled dose. A second sample (Cm.) was taken 1 h following the start of a timed 30-min infusion. All drugs were administered either in 50 or 100 ml of a 5% glucose solution. Actual times of all serum sample collections and drug administration were recorded and used for pharmacokinetic calculations. Aminoglycoside concentrations in serum were measured by a fluorescent polarization immunoassay (TDx; Abbott Diagnostics Division, Irwing, Tex.), and analyses were conducted within 8 h of sample collection. Serum samples were obtained through peripheral venipunctures in all the control patients and in 64 (87%) instances in the study group. The remaining 10 (13%) blood samples were drawn through Hickman catheters, as peripheral venipunctures were technically difficult.
Calculation of individual aminoglycoside pharmacokinetic parameters was performed by the method of Sawchuk et al. Ko is the infusion rate, in milligrams per hour; t is the time period of infusion, in hours; t1/2 is the half-life, in hours; T is the dosing interval, in hours; peak D is the desired Cmax, in micrograms per milliliter; and CL is clearance, in milliliters per minute.
The results obtained from the initial pharmacokinetic studies for each patient were used to determine the dosage required to achieve a Cma, of >20 and <30 ,ug/ml for amikacin or >6 and <10 ,ug/ml for gentamicin. Desired Cmin concentrations were <8 ,ug/ml for amikacin or <2 ,ug/ml for gentamicin.
After attainment of steady state with the calculated dosage, determination of the aminoglycoside level in serum was repeated by the method described above. If levels in serum were inappropriate, the dosage was recalculated. Aminoglycoside levels in serum were determined weekly to ensure that optimal therapeutic concentrations were maintained. Concentrations of ceftazidime and vancomycin in serum were not measured in any of the patients.
Calculation of pharmacokinetic parameters was conducted by using a proprietary spreadsheet computer program (SuperCalc 4 version 1.0; Computer Associates International) into which the equations were entered. Along with pharmacokinetic data, relevant clinical and laboratory information was recorded within the spreadsheet. Information consisted of weight; height; age; treatment protocol; number of days postchemotherapy; temperature; concomitant administration of parenteral nutrition and amphotericin B; total number of platelet and blood transfusions; creatinine level in serum; leukocyte count; hemoglobin; platelet count; blood urea nitrogen; and serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, and bilirubin concentrations. Development of ascites or pleural effusion; positive blood, sputum, or urine cultures; and, where appropriate, the percentage of bone marrow blast cells (defined as the percentage of 1,000 counted nucleated bone marrow cells) present at the time of original diagnosis were also noted. All clinical and laboratory data were recorded concurrently with each determination of the aminoglycoside concentration in serum in order to correlate any changes in pharmacokinetic parameters with the variables mentioned above within each course and between subsequent courses of aminoglycoside administration.
Nephrotoxicity was defined as a rise of the creatinine level in serum of >44 ,umol/liter from the base line. Ototoxicity was not assessed because of the difficulty in performing audiometric examinations in this patient population.
Creatinine CL was estimated by using the method described by Cockcroft and Gault (5). Estimation of kei was VOL. 34, 1990 703
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based on the following equation: 0.0024 (creatinine CL) + 0.01 (9) . Statistical analysis. A two-sample t test (two-tailed) and one-way analysis of variance (ANOVA) were used to determine statistical differences between group means. The Pearson product correlation coefficient (r), simple regression analyses, and coefficient of determination (R12) were used to determine correlations and associations. A probability of <0.05 was considered significant. All statistical analyses were conducted on a proprietary statistical software program (Statgraphics version 2.1, Statistical Graphics Corp.). (2, 4) . Aminoglycosides are widely used in empiric treatment of febrile episodes in neutropenic patients (33) . Because of the narrow range between subtherapeutic, therapeutic, and toxic concentrations, appropriate dosage calculation can only be achieved through determinations of the concentration in serum in these patients, who are often seriously ill (23, 30) . Several studies have demonstrated that an improved outcome in patients with gram-negative infections is directly related to the Cmax of the aminoglycoside (1, 17, 25-27).
Likewise, attainment of an adequate Cm,xfrom the first dose contributes to therapeutic efficacy (14) . Klastersky (19) has shown that as the absolute neutrophil count decreases, higher bactericidal activity in serum is required for successful treatment. A peak bactericidal activity in serum of at least 1:8 is required in neutropenic patients (absolute neutrophil count, <1,000), while in severely neutropenic patients (absolute neutrophil count, <100) peak bactericidal activity in serum of 1:16 is required. At lower aminoglycoside concentrations, synergism between the beta-lactam and the aminoglycoside may not occur. This can be overcome by increasing the dose of the aminoglycoside to attain a higher Cmax (19) . Trough aminoglycoside concentrations in serum have not been correlated with an improved outcome in patients with gram-negative infections (25) (26) (27) . Dosage nomograms and manufacturer-recommended doses are derived from either a specific patient population or, more commonly, healthy adults, rather than the populations for which the drug is intended (8) . The aminoglycosides exhibit wide inter-and intrapatient variabilities in their pharmacokinetic parameters (38) and are known to be affected by various disease states (30) Total aminoglycoside CL from the body exceeded creatinine CL significantly. These observations raise the possibility of enhanced renal or extrarenal elimination of aminoglycosides in patients with an underlying hematologic malignancy.
As mentioned above, no single factor that we recorded was associated with the observed increase in aminoglycoside V.S. Altered metabolic states (21) produced by the disease process may explain the increase in Vs.. An increased CL associated with a high percentage of blast cells in the bone marrow at the time of presentation in patients with acute leukemia and in patients with advanced lymphoma (stage IV) represents a previously unreported finding. It is also of interest that none of the pharmacokinetic parameters, including CL, showed significant changes after chemotherapy administration. Therefore, it is unlikely that the tumor burden alone is directly responsible for the observed alterations in aminoglycoside disposition. Increased CL may be associated with the severity or advanced state of the disease, but in order to establish a significant correlation, a large prospective trial analyzing CL and complete remission or overall survival would be required. We are, however, reluctant to draw any firm conclusions at this time from the small sample of patients that we studied.
The TDx assay (Abbott) has been shown to result in aminoglycoside pharmacokinetic parameters which differ slightly from those obtained by radioimmunoassay (31). This was not a factor in this study since the TDx was also used in the control group. We used two blood samples to determine the pharmacokinetic parameters. The two-sample method is comparable to the three-and four-sample methods described by Sawchuk et al. (32) , and no difference has been shown to exist between the two methods if appropriate steps are taken (35) . We realize that the two-sample method, despite the economic and time-saving benefits, is more apt to result in erroneous pharmacokinetic parameters than are the three-or four-sample methods if timing of administration and sampling are inaccurate. Nevertheless, we must point out that in all our patients, we waited until steady state was achieved and strict timing, both for administration and sampling, were adhered to.
The calculated parameters for the aminoglycoside V., CL, and tj,2 in patients without a malignancy corresponded to the results obtained in Western centers for similar patient groups (28) . The primary purpose for the inclusion of a control group in the study design was to eliminate ethnic differences as a cause of alteration in aminoglycoside disposition. Since the pharmacokinetic parameters obtained in the control group were similar to those obtained in Western patients, there is no reason to believe that patients of Middle Eastern origin have distinct aminoglycoside dispositions.
Most reported studies on empiric treatment of neutropenic febrile episodes, using an aminoglycoside, make no mention of pharmacokinetic analysis to optimize aminoglycoside therapy (11, 12, 20, 36) . Some investigators have used amikacin at a dose of 15 mg/kg per day administered every 6 or 12 h, with the average adult receiving 250 mg four times daily or 500 mg twice daily (11, 12, 20, 36 (30, 37, 38, 40) .
In summary, we reported aminoglycoside pharmacokinetic analysis to show increased V, CL, and dosage requirements in patients with an underlying hematologic malignancy. Our 
